Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q2 FY2017 Earnings Presentation
11 slides from Aurobindo Pharma's earnings presentation, Nov 14, 2016
Slide 1: Q2 FY16-17 Earnings Presentation
Q2 FY16-17 EARNINGS PRESENTATION 14th November 2016
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Business Highlights
Business Highlights Q2 FY16-17 Update Abbreviated New Drug Application (ANDA) 9 new ANDAs filed with USFDA (Oral – 6, Injectable – 3) 15 ANDAs Final approved by USFDA (Oral - 10, Injectable - 5) Launched 11 new products in US market; 7 Oral and 4 Injectables Cumulative transfer of 37 products
Slide 4: Consolidated Financial Highlights
Consolidated Financial Highlights Operating Income (including excise duty) increased by 12.2% to Gross Operating Income (INR Cr) INR 3,775.5 cr (US$ 564.6 Mn) Segment wise Sales Formulations - INR 3,003.8 cr; US – INR 1,735.1 cr EU – INR 813.4 cr ARV – INR 278.5 cr Emerging Market – INR 1
Slide 5: Consolidated Financial Performance
Consolidated Financial Performance Q2 Q2 % Q1 Q2 Value INR Cr % Chg PAT Reconciliation (INR Cr) FY17 FY16 Chg FY17 FY16 Formulations 3,003.8 2,673.1 12.4 3,032.1 (0.9) As per IGAAP 451.8 API 768.8 691.0 11.3 734.5 4.7 Impact on deferred tax (including on unrealized Formulations % of sales 79.6% 79.5
Slide 6: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-15 Mar-16 Sept-16 Closing Rate1 US$ = INR 62.50 66.255 66.615 690 748 586 Fx Loan restated in INR 4,312.3 4,956.7 3901.8 Rupee Loan 37.3 46.9 34.8 Sales Tax Deferment 54.9 41.9 0.5 Gross Debt 4,404.5 5,045.6 3,937.0 Cash Balance 450.8 805.2 711.2 N
Slide 7: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register
Slide 8: Gross Sales Break-Up
Gross Sales Break-Up FY15 FY16 FY17 INR Bn Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 H1 USA 11.1 11.6 11.8 13.3 47.7 14.1 14.7 15.6 16.3 60.8 17.0 17.4 34.4 Europe 8.0 7.7 8.6 7.7 31.9 7.4 7.6 7.8 8.4 31.3 8.3 8.1 16.4 Emerging Market 1.2 1.4 1.2 1.2 4.9 1.6 1.6 1.6 1.6 6.5 1.9 1.8 3.7 ARV 2.2 1.4 3.3 2.7
Slide 9: Filing details as on 30th Sept 2016
Filing details as on 30th Sept 2016 As at As at As at As at As at Category Approvals Mar 13 Mar 14 Mar 15 Mar 16 Sept 16 Formulations 284 (FA: 243, US* 269 336 376 398 412 TA:41) 1,465 Dossiers Europe** 1,341 1,542 1,756 2,224 2,381 (163 products) 178 Registrations SA** 314 334 345 376 388 (88 produ
Slide 10: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / Orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics)&Oph
Slide 11: Shareholding Pattern
Shareholding Pattern As on As on As on Group 31 Mar 15 31 Mar 16 30 Sept 16 Non-Promoter Holding 46.1% Promoter Group 54.0% 53.9% 53.9% FII 29.6% 27.4% 26.7% MF / Insurance 6.2% 7.2% 7.6% Other Bodies Corporates 1.6% 2.4% 3.1% Retail Investors 8.6% 9.1% 8.7% Total 100% 100% 100% Equity Shares (in Cr